Certainty After CRISPR | Tuesday April 20, 2021 | 3:00 pm–4:30 pm CEST / 9:00 am–10:30 am EDT | Free CMN Webinar

Certainty After CRISPR

Recent developments in gene-editing technologies have enabled researchers to delete, insert and change regions in genomes down to the single base level. These developments show great potential in gene editing-based next generation gene therapies. However, the primary outcome after nuclease-based gene editing is insertions and deletions (InDels) at the targeted locus in the genome. Importantly, recent observations have shown that in addition to the formation of InDels at the desired site, unexpected outcomes also occur after gene editing. Join Keyi Geng and Eric Paul Bennett in this two-part webinar discussing the nature of these unexpected gene editing outcomes and ways to detect and characterise both the expected and unexpected editing outcomes.

What you will learn from this webinar

  • Discover potential unintended modifications during and after CRISPR/Cas9-induced edits
  • See how targeted long-read sequencing can reveal otherwise undetected genome alterations
  • Gain insights about different methods to validate the accuracy and precision of small and large genome edits
  • Get an overview of the advantages and disadvantages of the different validation methods
Sign up to the Webinar

Certainty after CRISPR | Tuesday April 20, 2021 | 15:00 pm–16:30 pm CEST / 9:00 am –10:30 am EDT | Free CMN Webinar

 

Sorry - something went wrong, your inquiry has not been sent!!
Thanks for registering, more information will follow.

This webinar  is managed by CRISPR Medicine News (CMN). CMN is committed to protecting and respecting my privacy. CMN will guard my information responsibly and never share my email address.

By signing up, I authorise the webinar sponsors Samplix and COBO Technologies to contact me about their products. CRISPR Medicine News takes your privacy very seriously. We are able to produce and distribute this webinar for free because of the kind support of our partners. To keep our webinars free, we make the details you leave on the form available to Samplix and COBO Technologies. As such, we use legitimate interest as the basis for processing your data. Our partners may contact you about their products and/or services.

We, CRISPR Medicine News, may also contact you regarding future webinars and other similar news and events that may interest you.

I may revoke my consent at any given time by sending an email to: sales@crisprmedicinenews.com

Speakers

Keyi Geng, PhD Student at the Karolinska Institute, Sweden

Keyi Geng, PhD Student at the Karolinska Institute, Sweden

Where did the target region go? Unravelling odd CRISPR/Cas9-induced genomic alterations in human cells

Keyi received her Master's Degree from Shanghai Jiao Tong University (China) working on cerebral ischemia and cellular senescence. She is now a PhD student in Claudia Kutter's lab at the Karolinska Institute (Stockholm, Sweden), focusing on deciphering tRNA gene functionality using CRISPR-Cas9 and various sequencing technologies.

  • Two cancer model cell lines were modified with CRISPR-Cas9 to excise a promoter region, but show evidence that the target sequence is still present
  • Target-specific PCR and Sanger sequencing, however, appeared to confirm the absence of the region of interest
  • In-depth analysis revealed surprising events – including rearrangements and reinsertions – happening after CRISPR editing

Eric Paul Bennett, M.Sc., Dr. Med., COBO Technologies, Denmark

Eric Paul Bennett, M.Sc., Dr. Med., COBO Technologies, Denmark

Fast and sensitive detection of InDels induced by precise gene targeting

More than 3 decades ago Eric's research efforts in the field of Glycobiology were initiated and dedicated to shed light on the biosynthetic events controlling human mucin-type O-glycosylation. These efforts have uncovered the human GalNAc-T gene family as the largest glycosyltransferase enzyme family covering a single glycosidic linkage. By use of the recently emerged nuclease-editing technologies, such as ZFN, TALEN and CRISPR-Cas9, for the last 11 years, Dr. Bennett has focused on ways of establishing precision engineered isogenic cells lacking individual “glycogenes”.
These efforts have among others led to the establishment and publication of methods and workflows that address previously unmet needs in the field, which improve both the targeting and indel detection efficacy of precise genome editing applications. The technologies developed have a profound impact on the execution of precise genome editing in basic research and translational biosciences.

  • Brief survey of the pros and cons of the available gene editing InDel detection methodologies
  • Are InDels the only outcomes to be expected after gene editing?
  • Choice of “fit for purpose” InDel detection methodology
CMN Webinar - Certainty After CRISPR
Supported by
Supported by
Supported by
CMN Webinars - Your Gateway to CRISPR Medicine

If you have any questions or request for webinars, please contact us at: sales@crisprmedicinenews.com

Future CMN Webinars will be listed here.

Always stay updated - Sign up to weekly newsletter.

CMN Articles - CRISPR Off-target and Safety

 

 

close
Search CRISPR Medicine